公卫人

 找回密码
 立即注册

QQ登录

只需一步,快速开始

查看: 6640|回复: 3

[分享] Clinical Trial Methodology (2010)

[复制链接]
sampson2010 发表于 2015-5-29 12:42:00 | 显示全部楼层 |阅读模式

注册后推荐绑定QQ,之后方才可以使用下方的“用QQ帐号登录”。

您需要 登录 才可以下载或查看,没有账号?立即注册

x
61yEAoXGxnL.jpg - Z" z  h& ^, v( ?" t3 @
# n) v( p& ]' g7 ^* J; K8 v5 i
Title: Clinical Trial Methodology9 G) X6 ?) r; |
Author(s): Karl E. Peace, Din Chen
7 V3 Q1 {0 ]5 VSeries: Biostatistics Series       
% M3 J7 w1 Y- |" U; [& Q' ?Publisher: Chapman & Hall CRC
$ n- a! y% M& ]# L! [2 U: H1 EYear: 2010       
" Q. ]" L- F- _( P5 Z, \; x+ ^Edition: 1( e. S; V. S2 m: p% F% `
Language: English
/ M3 k% Q4 a& l- W9 |9 {" KPages: 420
+ Y  Z  [8 @5 m% [ISBN: 1584889179, 9781584889175, 1584889187, 9781584889182
$ R; B- R( H% i" ?1 }Size: 3 MB (2647392 bytes)  E' S) [+ ~% n0 _
Extension: pdf
6 B' `2 |3 f# R. m
2 X4 {0 z- ?: U  x2 y1 R# d' c
- A( Q5 F! z$ m- Y# S" A5 _* j
Features
+ p  W7 x6 G1 D/ K$ R! H, D" o3 z6 N5 W0 _
  • Reviews legislation pertinent to the clinical development of drugs
  • Discusses the processes of drug research and development within the context of a typical pharmaceutical company
  • Presents general biostatistical principles of clinical trials, including protocol development and statistical analysis plan development
  • Provides case studies of clinical trials for the development of drugs to treat panic attacks, duodenal ulcers, and Alzheimer’s disease; to reduce coronary heart disease risk; and to prevent gastric ulcers and angina
    + F+ D  q" l5 F$ ]! s% i6 k

$ K- n7 p' a. K( c( q' X  X3 \9 I$ B4 o' J& Q) R0 @3 f
8 [" q0 {* w, b+ V% w) L
Summary
2 N8 v% R- ]+ A1 t7 r% Y; Q3 q3 o0 _* }+ O8 M
Now viewed as its own scientific discipline, clinical trial methodology encompasses the methods required for the protection of participants in a clinical trial and the methods necessary to provide a valid inference about the objective of the trial. Drawing from the authors’ courses on the subject as well as the first author’s more than 30 years working in the pharmaceutical industry, Clinical Trial Methodology emphasizes the importance of statistical thinking in clinical research and presents the methodology as a key component of clinical research.
# ?+ d) K, K+ n; E4 s+ }$ [1 R1 q6 O) Q( S4 ^
From ethical issues and sample size considerations to adaptive design procedures and statistical analysis, the book first covers the methodology that spans every clinical trial regardless of the area of application. Crucial to the generic drug industry, bioequivalence clinical trials are then discussed. The authors describe a parallel bioequivalence clinical trial of six formulations incorporating group sequential procedures that permit sample size re-estimation. The final chapters incorporate real-world case studies of clinical trials from the authors’ own experiences. These examples include a landmark Phase III clinical trial involving the treatment of duodenal ulcers and Phase III clinical trials that contributed to the first drug approved for the treatment of Alzheimer’s disease.
- S$ v# o0 q' r" i5 ~( T+ x$ ^! z& A8 B9 R& P: I. X
Aided by the U.S. FDA, the U.S. National Institutes of Health, the pharmaceutical industry, and academia, the area of clinical trial methodology has evolved over the last six decades into a scientific discipline. This guide explores the processes essential for developing and conducting a quality clinical trial protocol and providing quality data collection, biostatistical analyses, and a clinical study report, all while maintaining the highest standards of ethics and excellence.4 g( \0 u& e* u$ j+ Z
' c( D1 A2 H! Q5 U  `
8 H% h" s3 k8 {! y* F

+ c& L2 ^" |1 `3 O& H5 d* xTable of Contents5 l/ M. C0 n3 j6 ]7 [$ }7 O

' R5 P1 r2 K8 s# ]8 X( qOverview of Clinical Trial Methodology
# Y! E+ o6 q  u) I/ |# MClinical Trials / O, p, l9 v2 J- ^# S& G+ v
Clinical Trial Methodology. [. B! X2 T  f0 g! ]( Z" C! k& ?  [
Summary of Clinical Trial Methodology
: v7 ]8 P! v. u8 {5 U: S
( k4 {1 y9 i* j( d* r( IOverview of the Drug Development Process and Regulation of Clinical Trials - d/ k, U$ w. G
Introduction4 g. F$ ]; }3 `" q- ^& e
The Drug Development Process- j$ a2 a- a, S; d! K) }
History of Drug Regulation
! @4 A9 |! e# K3 M. M/ Z1 r" EPrinciples of Adequate and Controlled Investigations
" }6 M5 Y& ?9 z; S: h2 IContent and Format of the IND! F/ I( f5 B; H8 Y- ^7 G8 L
Content and Format of the NDA7 T) Q# m" P$ c4 T4 w0 l
Organizational Structure of the FDA
0 o7 v5 M2 q2 M+ ^; R0 iThe FDA Review Process
& K9 A* v& b% V5 hLabeling and the Package Insert " {' ~5 a& K' ~6 _& k, p
Pharmaceutical Company Organization and Role of the Biostatistician. n! k8 j3 h, r4 j/ Y( E+ T
$ K" a8 h8 [- w3 E$ f  P, P
Ethical Considerations in the Design and Conduct of Clinical Trials
4 W8 a* n  m# G' oIntroduction7 U  f1 L% ?7 ^. J( @7 p7 s
History and Evolution of Ethical Considerations in Clinical Trials: Key Milestones
) v$ M. k$ W& p# l* |3 ~8 lIndependent Review Boards
. u" |/ X# W8 o6 ]2 PClinical Trial Ethics: Who Should Practice?2 x4 r2 B9 p! t4 l
Informed Consent, Sample Size, and Power
5 V0 k8 V6 c* uCommon Ethical Principles of Various Codes and Regulations
+ n) X2 V7 A! y+ G. Q! F' \+ E' A2 J, [" J3 ?) N& J- S
Sample Size Considerations in Clinical Trials Pre-Market Approval
  r+ T' H. ?2 x2 n# C4 M+ C9 M) oIntroduction$ y. _) ]) r! F1 x0 y& m5 b
Phases of Clinical Trials and Objectives 0 A: s6 M. Z5 g( K' [
The Clinical Development Plan: Pre-Market Approval- i% v2 ~  L. D
Sample Size Requirements
; j4 p' n9 l- T# {& m8 X2 |; PExamples) ^7 X$ s! w* [2 s3 W
Philosophical Issues, c9 S5 E0 _/ C+ y' p# D7 _

7 `' w; \5 R* T# Z! _Sequential, Group Sequential, Stochastic Curtailment, and Adaptive Design Procedures in Clinical Trials ) y- _* R& Q# G- n# r$ Z4 z
Introduction3 w9 `+ \0 B% D1 N+ [: V& g. k) U
Sequential Procedures' Q' @5 @0 |0 E! d6 @; p! a
Group Sequential Procedures$ b; P7 c1 p: v1 z1 I
Stochastic Curtailment
# F/ R0 k& o$ m0 d1 ]1 XAdaptively Designed Clinical Trials5 w1 q8 z/ r0 e8 S7 y

: O; ]. P1 i8 p3 H$ N( @Biostatistical Aspects of the Protocol
4 g/ ^/ D  D: v% q  dThe Background or Rationale 0 {4 q2 m9 T7 }9 `  l( N6 J3 x# }
Objective - E; D9 H$ M- k2 r
Plan of Study* }% ?8 C' w2 e6 p1 P
Statistical Analysis Section
* C9 U% h8 @% `6 W2 }Administration+ q* v5 [- }- k
Protocol References Section
- ^- s, b7 i0 B9 \
7 S$ G1 K  z) S& ~The Statistical Analysis Plan
3 C0 I$ C. Q7 g! G3 J" v' ]0 nIntroduction
+ j8 v6 k+ I$ |2 CProtocol Objective
  f4 V0 U- Q9 k* G$ C8 O, E7 X$ B' DEfficacy Data Collected and Protocol Schema
& y* a/ C- A% d4 H3 {0 n1 sPrimary and Secondary Efficacy Endpoints
) [: i2 u# K& p) `) {4 wObjectives, Translated as Statistical Hypotheses
0 e3 q4 t& w, H( NProtocol Design Features
  {+ T# d- O' Z6 AStatistical Analyses
5 ?* Z8 F/ M- h. ]
+ |: ^, `: I4 _: dPooling of Data from Multicenter Clinical Trials
! I, o& I" A. U: b9 X4 BIntroduction
* v. K6 L7 z1 R2 L5 xMulticenter Clinical Trial Experimental Setting
- c6 X: K; Q( p- f. W/ F! GPre-Study Planning 5 j* E9 L. S, p
Multicenter Clinical Trial Conduct
1 l% E- \- M% y/ PBiostatistical Analysis+ t' |/ _9 D8 Q; t) z4 R% u
% Q8 l* C8 H. x3 f! y9 F
Validity of Statistical Inference. O: D- Q# |. r4 C+ E
Introduction) C( m# B  _7 K9 x, O* w
Planning the Investigation
4 k6 [$ `. I) Y: W; Y) ~! ~2 `+ n6 W% tConducting the Investigation 1 e0 C) B$ B. i6 R8 M, r$ B
Statistical Analyses, Interpretation, and Inference
' v2 x* ~3 D; mReporting Results of Investigations$ S0 u9 {  X+ P! i
6 v; [: h( B# [4 C: E
Bioequivalence Clinical Trials
. F3 Q5 a2 I. [% J* R, n* oIntroduction
2 S' [0 y& T% QAbsorption, Distribution, Metabolism, and Excretion (ADME)
! {3 Z- B7 H5 I6 i/ DBioavailability
  L% Y, y/ ]0 e3 w: MFactors That Affect Bioavailability/ B0 G# C8 ]$ Y" Y* j
Blood Level Clinical Trials # {8 w" ]5 Y  K& n: j$ e6 S6 Q+ t/ b
Bioequivalence
" r/ f( j1 Q' b% N0 ?0 `6 E7 v9 X0 iDesign of Bioequivalence Trials! N% D- q( ]! O4 m3 m% p. N
Analysis of Bioequivalence Trials
. s# k# u- P9 Y3 IAnalysis of Ratios
" m& w+ f0 I- ~8 FPharmacokinetic Models
9 u5 H# J8 g1 R% M6 ^Support of Bioequivalence Trials in the Pharmaceutical Industry 0 [7 s3 B' A) A7 N/ R
Examples' O/ }4 m2 P) H

8 i' t% B' p2 ]; Z3 ^3 uDose and Frequency Determination from Phase II Clinical Trials in Stress Test-Induced Angina
- _5 j, [: `6 [$ b3 P' o( I9 @, x$ jIntroduction
9 u* X" H% {, O* ?Overview of Response Surface Methodology
2 e2 \3 G6 u; A% \" d) tFull Quadratic Response Surface Model
" G, @# @7 N5 h$ V  cPhase II Clinical Trial Program in Stress Test-Induced Angina
5 p. L. k+ t) |3 x+ A9 ~# o) t0 H3 O
Confirmation of Clinically Optimal Dosing in the Treatment of Duodenal Ulcers: A Phase III Dose Comparison Trial " |; P* P& _1 b* t) P
Introduction
, o" G8 O' H2 E. B* J- {4 KBackground
  G. C$ N% R: O, U% i7 i* tObjective ! q: i3 S0 A8 ?5 D5 E& O8 c2 n
Designing and Planning the Investigation
/ l+ w0 E+ G; E, ^5 B. HConducting the Investigation
3 u$ a0 i# H9 Y! j. KStatistical Analyses7 L! N5 P  F7 q8 o1 {8 d4 ~! M
Other Considerations
( _  ~( C0 L2 ]( Y* |9 lInnovative Aspects of the Clinical Trial Program
3 ]* s+ N) @; `& D: J! T
" b0 T. k8 J7 bPivotal Proof-of-Efficacy Clinical Trials in the Prevention of NANSAID-Induced Gastric Ulceration
/ [7 J  U9 x0 QIntroduction+ a3 ~$ D1 |+ _; a: Q5 K1 I& D* P
Rationale " c* F; k8 s% ~0 z
The Protocols
0 j, J: N1 ?! W' e) IMonitoring and Data Management
8 w& `1 K0 H( ?$ I2 ], RFDA Meeting
: M$ y) t& h8 D- N5 v: U) K% P7 F$ _2 y$ J: ]7 V, S
Clinical Trials in the Treatment of Alzheimer’s Disease Based upon Enrichment Designs$ z. E! U9 _# |  z5 P( u
Introduction: O3 F8 L# A6 y: O8 e! |
Enrichment Design Clinical Trials
7 m% _+ Y1 |# {4 N( d6 _9 f9 qObjective
/ R" B! Y% S5 g/ @/ m! X" J, pPrimary Efficacy Endpoints
* I7 v) y9 F% ]' ~, V" W  o3 jSample Size Determination
; b3 v( o) n. S$ I/ B2 aStatistical Methods
( U( l& H- Y( Y* g& xResults# h# H9 b9 H, N7 x; H8 C

+ L1 e% |, U8 E0 KA Clinical Trial to Establish Reduction of CHD Risk ; e& h! C1 V$ v7 U, U) n
Introduction" n/ s0 X1 B0 k1 n
Objective
- j. [" g- J: I' `. Z$ \( d1 |Designing and Planning the Investigation
" y. h. s# [! E  b5 lConducting the Investigation $ n$ J, k8 o% S) [% e7 K; n- [
Data Management * h" ]' U% a" H6 P
Statistical Analyses( U" x$ l! Q6 u- |
Results! u2 M: |- y3 k- e3 q
Summary
/ i! A0 v: Q% y4 x' I. @0 C
, W- D0 Z, B. _Pivotal Proof-of-Efficacy Clinical Trials in the Treatment of Panic Disorder ; V2 V. m; v2 q6 i  s
Introduction" o( u  G. E1 K1 z  T  _% x4 V3 Z
Design of Pivotal Proof-of-Efficacy Trials7 n& y. [  F# G( B% B
Traditional Statistical Analysis Methods . a" D! g: @6 X0 Q5 k: c
Overview of Efficacy Results of the Two Trials ' l5 f  h) c* v6 S3 k! s4 B
Alternative Design and Analysis Strategies
* `( q5 F6 e/ T4 }
: J( d4 j' R" n% E) J1 J" V0 bCombination Clinical Trials
" {, a0 m6 F$ N* U) ?Introduction: Z3 ]' F9 a5 N' o' O8 Y- b5 r
Two-by-Two Factorial Design
; K7 t0 p3 k0 |* }Effectiveness of the Combination
/ Z' W$ \% v" Y' c) T5 U) ~: a, ]Contribution of Components to the Effectiveness of the Combination 1 n1 N3 F$ F4 O4 Q, y
Factorial Designs in Other Clinical Development Areas4 @& l9 G! x5 [' D( I
Example 1: Actifed in the Treatment of SAR Following DESI Review; s5 O  B3 z6 I3 p, R
Example 2: Crossover Trial of Actifed in the Treatment of SAR
- f/ L" \, A' ~2 B' T; W3 nExample 3: Parallel Trial of Actifed in the Treatment of the Common Cold1 y& R# M7 f5 t4 P0 B& J9 x5 \
9 T) S# R6 I; T0 D. [8 A
Monitoring Clinical Trials for Adverse Events
! Q6 ?8 \: q: |1 kIntroduction. E2 j% S; Z1 F7 Z" d
Designing for Safety: Antibiotic Rash Example9 x7 m/ b+ m/ b9 U/ S% W
Designing for Safety: Hypokalemia Example
) T9 Z4 l: s7 q2 u' D& }0 f6 k5 Q& CDesigning for Safety: Hypertensive Rebound Example
- x6 x) p# a  k5 E$ z1 v7 d. sPremarket Approval Trials: Designed for Efficacy
: }) l. A) d  q9 b' L# X  MPremarket Approval Trials: Quality of Adverse Event Information, T* j9 N/ w. j0 p8 M: B
Monitoring for Safety9 t3 W' W" [4 M% R, R4 g/ x
Statistical Methodology: Individual Trial7 M( _5 M" J- V9 |
Example$ `0 b- M0 n8 `% ^0 G' |, i7 z
Statistical Methodology: Across Trials
- a) K3 P& `* I) P8 M/ O+ B2 _2 N8 B3 D" a- R: K. E% O3 U; C
Index
6 S1 c' s8 C8 d- {1 o5 y" Y9 |% X( S6 t" l3 z
References appear at the end of each chapter.
% }* \# r. ^4 }; Z+ W# E* N% @6 {  u. j! p  A
+ a" [7 v: f: J- V
- {) o- v$ P0 w$ N9 L/ w
Author(s) Bio6 w  N/ l6 Y4 q/ C" C, x$ I

% u1 W  ~/ K  |$ P& l. }Karl E. Peace is the Georgia Cancer Coalition Distinguished Cancer Scholar, founding director of the Center for Biostatistics, and professor of biostatistics in the Jiann-Ping Hsu College of Public Health at Georgia Southern University.( M- q/ ?8 ^* E' e

8 m* Q1 t% O4 h1 j/ L( `Din Chen is the Karl E. Peace Endowed Eminent Scholar Chair in Biostatistics and professor of biostatistics in the Jiann-Ping Hsu College of Public Health at Georgia Southern University.
. ~) F; }+ ?+ y+ z) _1 U, _$ r4 v3 O7 R2 ^' P3 L8 f
* f- G- S" E: {: \. x! B

# ~% x6 d, m- N: k2 N* y6 z$ l Clinical Trial Methodology (2010).pdf (2.52 MB, 下载次数: 100) , K" q9 ?* |) E2 Y

! n& c, o& r+ v/ u$ e4 O" W; J) W. ?+ F$ `
来自群组: RGCE

本帖被以下淘专辑推荐:

tljuly 发表于 2017-12-23 23:08:15 | 显示全部楼层
好书!!多谢分享
回复

使用道具 举报

芬2012 发表于 2018-4-23 14:29:53 | 显示全部楼层
已下载,感谢分享
回复

使用道具 举报

1582891835 发表于 2018-7-26 10:51:39 | 显示全部楼层
多谢楼主分享~
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

手机版|会员|至尊|接种|公卫人 ( 沪ICP备06060850号-3 )

GMT+8, 2024-6-11 03:15 , Processed in 0.112147 second(s), 9 queries , Gzip On, MemCached On.

Powered by Discuz! X3.4

© 2001-2023 Discuz! Team.

快速回复 返回顶部 返回列表